Modular tumor endoprostheses in surgical palliation of long-bone metastases: a reduction in tumor burden and a durable reconstruction

World Journal of Surgical Oncology

Research

Tim Sauer¹  Steffen Hoell²  Jendrik Hardes³  Juliane Krebs³  Arne Streitbuerger³  Georg Gosheger³  Marcel-Philipp Henrichs³  Markus Nottrott³  Gurpal Singh⁴ 

[1] Department of Oncology, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149, Muenster, Germany;Department of Orthopaedic Surgery, Paracelsus Hospital Osnabrueck, Am Natruper Holz 69, 49076, Osnabrueck, Germany;Department of Orthopaedic Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149, Muenster, Germany;Department of Orthopaedic Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149, Muenster, Germany;University Orthopaedics, Hand and Reconstructive Microsurgery Cluster, National University Health System, Singapore, Singapore;

关键词: Bone metastasis;    Modular;    Surgical reconstruction;    Survival;    Tumor burden;    Tumor endoprostheses;   

DOI  :  10.1186/1477-7819-12-330

 received in 2014-03-29, accepted in 2014-10-20,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundSurgical treatment of bone metastases has become increasingly important as patients live longer with metastatic cancer and one of the main aims is a long-lasting reconstruction which survives the patient. Conventional osteosynthesis may not be able to achieve this objective in the context of modern day cancer care.MethodsThis study evaluates the oncological outcomes, treatment-related complications, and function after resection of metastases and reconstruction with modular tumor endoprostheses in 80 patients. All patients who underwent surgical treatment with modular tumor prostheses for bone metastases from 1993 to 2008 were traced by our tumor database and clinical information was recorded from patient case.ResultsMean age was 63 years. The most common primary tumors were renal cell (47%), breast (21%), and lung (8%). The proximal femur was affected in 45%, proximal humerus in 26%, and the distal femur in 17% of cases. In 22 cases, the tumor prosthesis was implanted during a revision operation. Mean overall survival after surgery was 2.9 years. Overall survival rate was 70% at one year and 20% at five years. Implant survival was 83% after one year and 74% at five years. Overall rate of operative revision was 18%.ConclusionsOur data collectively suggest that despite higher costs, implantation of modular tumor endoprostheses may be a suitable treatment for bone metastases with a low complication rate and rapid improvement in function in appropriately selected patients.

【 授权许可】

Unknown   
© Henrichs et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.